Valuation : GlaxoSmithKline Pharmaceuticals Limited

Market Cap 517B 5.44B 4.68B 4.39B 4.01B 7.54B 7.59B 52.07B 20.26B 262B 20.41B 19.97B 868B P/E 2027 *
44.6x
P/E 2028 * 38.7x
Enterprise Value 517B 5.44B 4.68B 4.39B 4.01B 7.54B 7.59B 52.07B 20.26B 262B 20.41B 19.97B 868B EV / Sales 2027 *
12.2x
EV / Sales 2028 * 11x
Free-Float
-
Yield 2027 *
0.97%
Yield 2028 * 0.97%

Last Transcript : GlaxoSmithKline Pharmaceuticals Limited

1 day-1.91%
1 week+2.19%
Current month+12.86%
1 month+12.86%
3 months+35.90%
6 months+20.64%
Current year+21.20%
1 week 2,920.55
Extreme 2920.55
3,121.1
1 month 2,508.5
Extreme 2508.5
3,121.1
Current year 2,088
Extreme 2088
3,121.1
1 year 2,088
Extreme 2088
3,121.1
3 years 1,387.9
Extreme 1387.9
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 2022-11-30
Director of Finance/CFO - 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-07-07
Director TitleAgeSince
Chairman 73 2019-03-31
Director/Board Member 59 2020-05-17
Director/Board Member 67 2022-05-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.91%+2.19%+6.78%+109.70% 5.44B
-1.52%-7.23%+57.90%+108.72% 1,031B
-0.82%-2.63%+50.05%+64.43% 641B
+0.37%-3.06%+21.87%+74.48% 453B
-1.37%-5.99%+33.82%+33.77% 349B
+6.13%+3.05%+28.64%+46.25% 290B
+0.33%-0.94%+1.23%+12.51% 252B
-0.59%-3.15%+49.83%+67.70% 232B
+0.43%-2.04%-19.71%-53.98% 201B
+0.45%-0.27%+29.84%+91.34% 181B
Average +0.55%-2.26%+26.03%+55.49% 363.52B
Weighted average by Cap. +0.85%-3.96%+37.18%+65.34%

Financials

2027 *2028 *
Net sales 42.53B 447M 385M 361M 330M 620M 624M 4.28B 1.67B 21.57B 1.68B 1.64B 71.41B 47.17B 496M 427M 401M 366M 687M 692M 4.75B 1.85B 23.92B 1.86B 1.82B 79.19B
Net income 11.61B 122M 105M 98.65M 90.06M 169M 170M 1.17B 455M 5.89B 458M 448M 19.5B 13.36B 140M 121M 114M 104M 195M 196M 1.35B 524M 6.78B 527M 516M 22.44B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
26-09-01 2,994.70 -1.91% 2,956
26-08-31 ₹3,053.10 -1.71% 3,431
26-08-28 ₹3,106.10 +1.23% 2,423
26-08-27 ₹3,068.35 +1.35% 6,205
26-08-26 ₹3,027.50 +1.59% 68,949
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3,053.10INR
Average target price
3,081.00INR
Spread / Average Target
+0.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock